Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vyxeos + gilteritinib
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Vyxeos + gilteritinib is a combination therapy being evaluated for the treatment of relapsed or refractory FLT3-mutated acute myeloid leukemia (AML). Vyxeos (CPX-351) is a liposomal encapsulation of daunorubicin and cytarabine in a fixed 1:5 molar ratio, designed to maintain synergistic drug concentrations in the bone marrow and tumor microenvironment. Daunorubicin is an anthracycline that inhibits topoisomerase II and intercalates DNA, while cytarabine is an antimetabolite that inhibits DNA polymerase. Gilteritinib is an oral small-molecule inhibitor of FMS-like tyrosine kinase 3 (FLT3) and AXL. This combination aims to provide cytotoxic chemotherapy alongside targeted inhibition of the FLT3 mutation, which is a common driver of poor prognosis and resistance in AML.
- Brand names
- VyxeosXospata
- Other names
- liposomal daunorubicin-cytarabinegilteritinib fumarate
02
Targets
AXL (AXL receptor tyrosine kinase)TOP2A (DNA topoisomerase II)DNA polymerase familyDNAFLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on Vyxeos + gilteritinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vyxeos + gilteritinib.